Cardiol Therapeutics Files Annual Meeting Documents
Ticker: CRDL · Form: 6-K · Filed: May 28, 2024 · CIK: 1702123
| Field | Detail |
|---|---|
| Company | Cardiol Therapeutics INC. (CRDL) |
| Form Type | 6-K |
| Filed Date | May 28, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, annual-meeting, corporate-governance
TL;DR
Cardiol Therapeutics dropped its annual meeting docs, shareholders get to vote.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on May 28, 2024, to report on its Annual General Meeting of Shareholders. The filing includes the Notice of Annual General Meeting, Management Information Circular, Form of Proxy, and Notice of Availability of Proxy Materials. The company is incorporated in Ontario, Canada, and its fiscal year ends on December 31.
Why It Matters
This filing provides shareholders with essential information and materials for the upcoming Annual General Meeting, allowing them to participate in corporate governance.
Risk Assessment
Risk Level: low — This is a routine administrative filing related to an annual shareholder meeting, not indicating new financial or operational risks.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Filer of the 6-K report
- May 28, 2024 (date) — Filing date of the 6-K
- Ontario, Canada (location) — Location of the company's principal executive offices
- December 31 (date) — Company's fiscal year end
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report on the Notice of Annual General Meeting of Shareholders, Management Information Circular, Form of Proxy, and Notice of Availability of Proxy Materials for Cardiol Therapeutics Inc.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on May 28, 2024.
Where are Cardiol Therapeutics Inc.'s principal executive offices located?
Cardiol Therapeutics Inc.'s principal executive offices are located at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
What is Cardiol Therapeutics Inc.'s fiscal year end?
Cardiol Therapeutics Inc.'s fiscal year end is December 31.
Which exhibits are submitted with this Form 6-K?
The exhibits submitted with this Form 6-K are: 99.1 Notice of Annual General Meeting of Shareholders, 99.2 Management Information Circular, 99.3 Form of Proxy, and 99.4 Notice of Availability of Proxy Materials.
Filing Stats: 210 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2024-05-28 11:43:29
Filing Documents
- tm2415640d1_6k.htm (6-K) — 11KB
- tm2415640d1_ex99-1.htm (EX-99.1) — 15KB
- tm2415640d1_ex99-2.htm (EX-99.2) — 768KB
- tm2415640d1_ex99-3.htm (EX-99.3) — 7KB
- tm2415640d1_ex99-4.htm (EX-99.4) — 8KB
- image_006.jpg (GRAPHIC) — 5KB
- tm2415640d1_ex99-2sp001img01.jpg (GRAPHIC) — 27KB
- tm2415640d1_ex99-2sp001img02.jpg (GRAPHIC) — 86KB
- tm2415640d1_ex99-3img001.jpg (GRAPHIC) — 169KB
- tm2415640d1_ex99-3img002.jpg (GRAPHIC) — 181KB
- 0001104659-24-065445.txt ( ) — 1455KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: May 28, 2024 By: /s/ Chris Waddick Name: Chris Waddick Title: Chief Financial Officer